[Current treatment options for myelodysplastic syndromes].
Nolte
F
F
III. Medizinische Klinik, Hämatologie & Onkologie, Universitätsmedizin Mannheim, Mannheim. florian.nolte@med-ma.uni-heidelberg.de
Hofmann
W-K
WK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D015913:Chelation Therapy; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics; D005260:Female; D006801:Humans; D019190:Iron Overload / Q000209:etiology / Q000628:therapy; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D010166:Palliative Care; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide; D001374:Azacitidine